Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
J. S. Frenel*, J. W. Kim, N. Aryal, R. Asher, D. Berton, L. Vidal, P. Pautier, J. A. Ledermann, R. T. Penson, A. M. Oza, J. Korach, T. Huzarski, S. Pignata, N. Colombo, T. W. Park-Simon, K. Tamura, G. S. Sonke, A. E. Freimund, C. K. Lee, E. Pujade-Lauraine
Research output: Contribution to journal › Article › peer-review
94Scopus
citations
Fingerprint
Dive into the research topics of 'Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial'. Together they form a unique fingerprint.